Payment overview · 2025
General Payments
$1,626.99
63 reported records · 19 companies
Healthcare provider profile · identity verified
Muhammad A Khan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAGINAW, MI · NPI 1881896975
Verified facts
What the public records show
CMS Open Payments records show Muhammad A Khan, MD received $1,626.99 in general payments during 2025 across 63 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARANESP as an associated drug or biological on 16 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Aranesp by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 363 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 363 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1440 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Gemtesa by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $329.06 | 20.2% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $319.28 | 19.6% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $225.50 | 13.9% | 9 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $121.06 | 7.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.00 | 5.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $87.13 | 5.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $71.46 | 4.4% | 4 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $59.82 | 3.7% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $53.27 | 3.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $45.72 | 2.8% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.64 | 2.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $37.66 | 2.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.11 | 2.0% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $22.47 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.80 | 1.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.17 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.66 | 1.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.74 | 0.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.44 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,626.99 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $319.28 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $266.11 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $236.93 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $225.50 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $214.08 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $121.06 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $81.08 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $71.46 | 4 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $59.82 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $53.27 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.74 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.74 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $45.72 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.26 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $41.64 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.16 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $37.66 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1440 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 93 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 114 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 363 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 131 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 56 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 161 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ARANESP open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 13 recipient NPIs · example record 1227128438 |
Aranesp · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
118 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
69 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
93 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
363 | 61 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
87 | 83 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
152 | 106 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
161 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
363 | 61 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
70 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
131 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
31 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1440 | 155 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
77 | 25 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
114 | 13 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1920 | 420 |
| Eliquis | Apixaban | 1440 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 1295 | 219 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1164 | 186 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1122 | 156 |
| Gabapentin | Gabapentin | 1115 | 165 |
| Potassium Chloride | Potassium Chloride | 954 | 204 |
| Furosemide | Furosemide | 868 | 180 |
| Metoprolol Tartrate | Metoprolol Tartrate | 794 | 175 |
| Sertraline Hcl | Sertraline Hcl | 726 | 114 |
| Tamsulosin Hcl | Tamsulosin Hcl | 696 | 148 |
| Lisinopril | Lisinopril | 670 | 146 |
| Pantoprazole Sodium | Pantoprazole Sodium | 660 | 143 |
| Metoprolol Succinate | Metoprolol Succinate | 463 | 124 |
| Bumetanide | Bumetanide | 458 | 96 |
| Losartan Potassium | Losartan Potassium | 454 | 109 |
| Carvedilol | Carvedilol | 447 | 85 |
| Donepezil Hcl | Donepezil Hcl | 438 | 83 |
| Metformin Hcl | Metformin Hcl | 398 | 95 |
| Bethanechol Chloride | Bethanechol Chloride | 396 | 59 |
| Tramadol Hcl | Tramadol Hcl | 387 | 67 |
| Omeprazole | Omeprazole | 377 | 136 |
| Levetiracetam | Levetiracetam | 367 | 52 |
| Jardiance | Empagliflozin | 363 | 61 |
| Hydralazine Hcl | Hydralazine Hcl | 358 | 81 |
| Escitalopram Oxalate | Escitalopram Oxalate | 347 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 346 | 81 |
| Mirtazapine | Mirtazapine | 328 | 78 |
| Simvastatin | Simvastatin | 319 | 80 |
| Baclofen | Baclofen | 307 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 298 | 67 |
| Allopurinol | Allopurinol | 286 | 63 |
| Midodrine Hcl | Midodrine Hcl | 283 | 64 |
| Alprazolam | Alprazolam | 281 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 277 | 78 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 274 | 25 |
| Buspirone Hcl | Buspirone Hcl | 271 | 48 |
| Montelukast Sodium | Montelukast Sodium | 270 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 268 | 51 |
| Trazodone Hcl | Trazodone Hcl | 238 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 231 | 42 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 225 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 101 |
| Ropinirole Hcl | Ropinirole Hcl | 214 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 196 | 76 |
| Memantine Hcl | Memantine Hcl | 196 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 195 | 75 |
| Warfarin Sodium | Warfarin Sodium | 195 | 15 |
| Lorazepam | Lorazepam | 186 | 38 |
| Divalproex Sodium | Divalproex Sodium | 185 | 29 |
| Cephalexin | Cephalexin | 180 | 95 |
| Fluoxetine Hcl | Fluoxetine Hcl | 171 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 168 | 34 |
| Risperidone | Risperidone | 167 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 161 | 44 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 152 | 106 |
| Alendronate Sodium | Alendronate Sodium | 150 | 24 |
| Spironolactone | Spironolactone | 148 | 40 |
| Albuterol Sulfate | Albuterol Sulfate | 146 | 38 |
| Meloxicam | Meloxicam | 144 | 37 |
| Pregabalin | Pregabalin | 143 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 142 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 140 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 134 | 30 |
| Benztropine Mesylate | Benztropine Mesylate | 133 | suppressed |
| Olanzapine | Olanzapine | 132 | 30 |
| Ozempic | Semaglutide | 131 | 26 |
| Atenolol | Atenolol | 130 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 128 | 53 |
| Clonazepam | Clonazepam | 126 | 16 |
| Enulose | Lactulose | 124 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 18 |
| Glipizide | Glipizide | 119 | 30 |
| Myrbetriq | Mirabegron | 118 | 12 |
| Xarelto | Rivaroxaban | 116 | 18 |
| Gemtesa | Vibegron | 114 | 13 |
| Methocarbamol | Methocarbamol | 111 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 110 | 32 |
| Calcitriol | Calcitriol | 109 | 24 |
| Entresto | Sacubitril/Valsartan | 108 | 19 |
| Prednisone | Prednisone | 107 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 106 | 21 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 106 | 48 |
| Latanoprost | Latanoprost | 104 | 31 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 101 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 101 | 35 |
| Sucralfate | Sucralfate | 100 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 97 | 53 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 15 |
| Farxiga | Dapagliflozin Propanediol | 93 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 93 | 27 |
| Nifedipine Er | Nifedipine | 90 | 29 |
| Lactulose | Lactulose | 89 | 24 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 87 | 83 |
| Paliperidone Er | Paliperidone | 86 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 86 | 43 |
| Finasteride | Finasteride | 85 | 18 |
| Famotidine | Famotidine | 84 | 40 |
| Lamotrigine | Lamotrigine | 82 | 14 |
| Liothyronine Sodium | Liothyronine Sodium | 82 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 80 | 43 |
| Lacosamide | Lacosamide | 79 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 77 | 25 |
| Metolazone | Metolazone | 77 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 77 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 73 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 71 | 15 |
| Trintellix | Vortioxetine Hydrobromide | 71 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 70 | suppressed |
| Bupropion Xl | Bupropion Hcl | 70 | suppressed |
| Fluconazole | Fluconazole | 70 | 45 |
| Trulicity | Dulaglutide | 70 | 18 |
| Brilinta | Ticagrelor | 69 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 69 | suppressed |
| Mounjaro | Tirzepatide | 68 | 11 |
| Primidone | Primidone | 68 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 20 |
| Sevelamer Carbonate | Sevelamer Carbonate | 66 | 11 |
| Ezetimibe | Ezetimibe | 65 | 19 |
| Glimepiride | Glimepiride | 65 | 15 |
| Scopolamine | Scopolamine | 65 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 64 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 63 | 27 |
| Methylprednisolone | Methylprednisolone | 63 | 37 |
| Carbamazepine | Carbamazepine | 62 | suppressed |
| Amantadine | Amantadine Hcl | 61 | suppressed |
| Aripiprazole | Aripiprazole | 61 | 17 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 59 | 40 |
| Carbamazepine Er | Carbamazepine | 58 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 58 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 16 |
| Rexulti | Brexpiprazole | 56 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 56 | 14 |
| Nitroglycerin | Nitroglycerin | 55 | 45 |
| Levofloxacin | Levofloxacin | 54 | 41 |
| Topiramate | Topiramate | 53 | 11 |
| Torsemide | Torsemide | 52 | suppressed |
| Diazepam | Diazepam | 51 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 51 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | 15 |
| Novolog Flexpen | Insulin Aspart | 49 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | 17 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 47 | suppressed |
| Fentanyl | Fentanyl | 47 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Amoxicillin | Amoxicillin | 46 | 31 |
| Verapamil Er | Verapamil Hcl | 46 | suppressed |
| Hydrocortisone | Hydrocortisone | 45 | 15 |
| Linzess | Linaclotide | 45 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 45 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 44 | 32 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 44 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | 13 |
| Arnuity Ellipta | Fluticasone Furoate | 42 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 21 |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Lovastatin | Lovastatin | 41 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 41 | 21 |
| Cinacalcet Hcl | Cinacalcet Hcl | 40 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 40 | suppressed |
| Haloperidol | Haloperidol | 40 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Bicalutamide | Bicalutamide | 38 | suppressed |
| Clonidine | Clonidine | 38 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 38 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | 31 |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 36 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 14 |
| Nadolol | Nadolol | 36 | suppressed |
| Silodosin | Silodosin | 36 | suppressed |
| Xifaxan | Rifaximin | 35 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 34 | suppressed |
| Nystatin | Nystatin | 34 | 23 |
| Ondansetron Odt | Ondansetron | 34 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | 12 |
| Meclizine Hcl | Meclizine Hcl | 32 | 18 |
| Megestrol Acetate | Megestrol Acetate | 32 | 13 |
| Novolog | Insulin Aspart | 32 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 31 | 30 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 31 | 13 |
| Labetalol Hcl | Labetalol Hcl | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | 12 |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 29 | suppressed |
| Nyamyc | Nystatin | 29 | 23 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 28 | 12 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 28 | 12 |
| Ramelteon | Ramelteon | 28 | 14 |
| Anastrozole | Anastrozole | 27 | 13 |
| Drizalma Sprinkle | Duloxetine Hcl | 27 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 26 | suppressed |
| Phenytoin | Phenytoin | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 15 |
| Celecoxib | Celecoxib | 25 | 11 |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 25 | 12 |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 25 | suppressed |
| Xcopri | Cenobamate | 25 | suppressed |
| Cartia Xt | Diltiazem Hcl | 24 | suppressed |
| Humalog | Insulin Lispro | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | 12 |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | suppressed |
| Restasis | Cyclosporine | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | 11 |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 12 |
| Austedo Xr | Deutetrabenazine | 22 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 22 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Clozapine | Clozapine | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 13 |
| Valsartan | Valsartan | 21 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 21 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 20 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Dexamethasone | Dexamethasone | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 13 |
| Linezolid | Linezolid | 19 | 12 |
| Prednisolone Acetate | Prednisolone Acetate | 19 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Admelog Solostar | Insulin Lispro | 18 | suppressed |
| Avycaz | Ceftazidime/Avibactam | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 18 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Mesalamine Er | Mesalamine | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Alogliptin | Alogliptin Benzoate | 15 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | 11 |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | 14 |
| Rhopressa | Netarsudil Mesylate | 15 | suppressed |
| Aranesp | Darbepoetin Alfa In Polysorbat | 14 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Equetro | Carbamazepine | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,626.99 · 63 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, COLLAGENASE SANTYL, CREXONT, ELIQUIS, FARXIGA, FUROSCIX, GEMTESA, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, NUZYRA, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, Veozah, Wegovy, YUPELRI, ZEPBOUND | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error